Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Interim REFRESH results demonstrating that among 67 patients (approximately half oxybate naïve, 37% switches from twice-nightly oxybates, and the remainder previous twice-nightly oxybate users); ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

If your portfolio includes an index fund, you may need to review and adjust your holdings. Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader.

ACE indicates angiotensin-converting enzyme; AHI, apnea-hypopnea index; BMI, body mass index; BP, blood pressure; IQR, interquartile range; and OSA, obstructive sleep apnea. Spironolactone prescribed ...

In this paper, we proposed a snore-based apnea and hypopnea events classification approach. Firstly, we define the snores after the apnea event and during the hypopnea event as apnea-event-snore (AES) ...

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and refers to a wide spectrum of histological abnormalities ranging from simple steatosis (HE) to ...

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

Home sleep apnea tests (HSATs) use sophisticated sensors and algorithms to monitor your breathing patterns, oxygen levels, ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

In a prior Australian Phase 2 clinical trial, IHL-42X was shown to reduce the Apnea-Hypopnea Index ("AHI”) in all dosage strengths, with the lowest dose reducing AHI by an average of 51 percent ...